Branded generics gain ground as drugmakers balance cost and trust

The global market for branded generics is expanding rapidly, reflecting mounting pressure on healthcare systems to contain costs while maintaining patient confidence in treatment quality.

According to analysis from The Insight Partners, the sector is projected to grow from $258.9bn in 2023 to $570.4bn by 2031, implying annual growth of just over 10 per cent. The rise underscores the increasing role of off-patent medicines sold under brand names as a middle ground between low-cost generics and higher-priced originator drugs.

Branded generics — copies of medicines marketed after patent expiry but under a distinct label — have become a strategic tool for pharmaceutical companies seeking to preserve market share while appealing to cost-conscious healthcare providers. Approval pathways such as the Abbreviated New Drug Application require therapeutic equivalence to the original product, enabling companies to compete on price without sacrificing clinical credibility.

Three structural drivers underpin the market’s expansion. First, governments across both developed and emerging economies are actively promoting generic uptake as a means of curbing healthcare expenditure. Policies encouraging substitution and reimbursement have helped embed generics deeply into prescribing practices.

Second, the economic impact is substantial. Data from the Food and Drug Administration suggest generic medicines have generated more than $2.2tn in savings for the US healthcare system over the past decade. Today, more than 90 per cent of prescriptions in the US are filled with generic alternatives, highlighting their central role in clinical practice.

Third, branded generics are increasingly intersecting with more tailored approaches to treatment. Evidence indicating that certain generics can match branded drugs in outcomes — including in cardiovascular care — has supported broader acceptance among clinicians, particularly in chronic disease management.

The market spans a wide range of therapeutic areas, from oncology and diabetes to cardiovascular and neurological disorders. Anti-hypertensive drugs remain a dominant category, reflecting the global prevalence of high blood pressure and the need for long-term, affordable therapy. Distribution continues to be led by hospital and retail pharmacies, though online channels are gaining traction as digital health platforms expand.

Regionally, North America remains the largest market, supported by established regulatory frameworks and payer systems that incentivise generic substitution. Asia-Pacific, however, is expected to deliver the fastest growth, driven by expanding healthcare access and large patient populations in countries such as India and China, alongside increasing manufacturing capacity.

Competition is intensifying among global drugmakers including Teva Pharmaceutical Industries, Sanofi and AstraZeneca, as well as specialist generics producers. Companies are seeking to differentiate through portfolio breadth, regulatory expertise and the ability to build brand recognition in markets where trust remains a key determinant of prescribing behaviour.

For pharmaceutical groups, branded generics also offer operational advantages. They can often be developed using existing capabilities and launched rapidly after patent expiry, allowing companies to capture value without the risks associated with early-stage research.

As healthcare systems face rising demand and constrained budgets, the segment is likely to play an increasingly prominent role. For policymakers and industry alike, branded generics represent both a commercial opportunity and a mechanism to broaden access to essential medicines without significantly increasing costs.